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G protein-coupled receptor 35 (GPR35) is an orphan receptor, discovered in 1998, that has
garnered interest as a potential therapeutic target through its association with a range of
diseases. However, a lack of pharmacological tools and the absence of convincingly deﬁned
endogenous ligands have hampered the understanding of function necessary to exploit it
therapeutically. Although several endogenous molecules can activate GPR35 none has yet
been conﬁrmed as the key endogenous ligand due to reasons that include lack of biological
speciﬁcity, non-physiologically relevant potency and species ortholog selectivity. Recent
advances have identiﬁed several highly potent synthetic agonists and antagonists, as well
as agonists with equivalent potency at rodent and human orthologs, which will be useful
as tool compounds. Homology modeling and mutagenesis studies have provided insight
into the mode of ligand binding and possible reasons for the species selectivity of some
ligands. Advances have also been made in determining the role of the receptor in disease.
In the past, genome-wide association studies have associated GPR35 with diseases such
as inﬂammatory bowel disease, type 2 diabetes, and coronary artery disease. More recent
functional studies have implicated it in processes as diverse as heart failure and hypoxia,
inﬂammation, pain transduction and synaptic transmission. In this review, we summarize
the progress made in understanding the molecular pharmacology, downstream signaling
and physiological function of GPR35, and discuss its emerging potential applications as a
therapeutic target.
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G protein-coupled receptors are historically the most success-
ful group of drug targets, and account for some 30–40% of
approved drugs on the market today (Drews, 2000; Hopkins and
Groom, 2002; Rask-Andersen et al., 2011). Indeed, several GPCR
ligands are among the worldwide 100 best-selling pharmaceu-
tical compounds (Zambrowicz and Sands, 2003). The success
of GPCRs as therapeutic targets stems from their role as trans-
ducers of extracellular signals across the cell membrane and
modulators of intracellular signaling, therefore bypassing the need
for membrane-permeable ligands. Many GPCRs also contribute
directly to the pathophysiology of disease, making them ideal
as drug targets. However, despite their success, it is estimated
that only 59 of the 370 non-olfactory GPCRs have been suc-
cessfully exploited as drug targets, suggesting that the remainder
may play largely modulatory roles unsuitable for this purpose or
that there still exists great potential within the GPCR drug devel-
opment arena (Sams-Dodd, 2005; Gashaw et al., 2011; Garland,
2013).
Abbreviations: BRET, Bioluminescence Resonance Energy Transfer; [Ca2+]i , intra-
cellular Ca2+; cGMP, cyclic guanosine 3′ 5′ monophosphate; DMR, dynamic mass
redistribution; EC50, half-maximal effective concentration; eYFP, enhanced yellow
ﬂuorescent protein; GPCR,G protein-coupled receptor; GWAS, genome-wide asso-
ciation study; HEK, human embryonic kidney; IBD, inﬂammatory bowel disease;
LPA, lysophosphatidic acid; qRT-PCR, quantitative reverse transcriptase PCR; SNP,
single nucleotide polymorphism.
Orphan GPCRs (receptors that have not yet been associated
with being activated by an endogenously produced ligand) provide
a means by which to expand the repertoire of drug targets. For
example, the orexin receptors, deorphanized in 1988, are the tar-
gets of the recently approved sleep-aid medication, suvorexant
(Jacobson et al., 2014). Moreover, many other orphan or recently
deorphanized GPCRs display therapeutically relevant tissue dis-
tribution proﬁles and/or have links to disease (Civelli et al., 2013;
Garland, 2013). One such orphan GPCR is G protein-coupled
receptor 35 (GPR35). However, despite this, in the 16 years since
its discovery (O’Dowd et al., 1998), GPR35 remains poorly char-
acterized and has been slow to amass interest. This stems from
a lack of selective and potent tool compounds with which to
probe GPR35 pharmacology and pathophysiology, with added
complications including signiﬁcant species selectivity issues (Jenk-
ins et al., 2011, 2012; Funke et al., 2013; Neetoo-Isseljee et al., 2013)
and the lack of consensus on the identity of the endogenous lig-
and (Mackenzie et al., 2011; Milligan, 2011). Here we provide an
overview of updates in the ﬁeld of GPR35 pharmacology, physiol-
ogy and pathophysiology, and discuss how GPR35 is emerging as
a GPCR with considerable therapeutic potential.
ENDOGENOUS LIGANDS FOR GPR35
A number of endogenous molecules have been reported to act as
agonists at GPR35 (Table 1). However, a number of these show
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Table 1 | Reported endogenous ligands with activity at GPR35.
Name Structure Action Potency (EC50) Comments Reference
LPA Unknown Not reported Phospholipid derivative;
elevates [Ca2+]i through
an unknown mechanism;
activity at GPR35 not
conﬁrmed with a GPR35
antagonist; does not
recruit β-arrestin-2
Oka et al. (2010),
Southern et al. (2013)
Kynurenic
acid
Partial agonist
(Human) full
agonist (Rat)
Human: 217 μM
Rat: 66 μM
Metabolite of
L-tryptophan
Wang et al. (2006),
Jenkins et al. (2011)
cGMP Partial agonist Human: 131 μM Cyclic nucleotide derived
from GTP
Southern et al. (2013)
DHICA Partial agonist Human: 22 μM
(DMR 24 μM)
Intermediate in the
biosynthesis of melanin
Deng et al. (2012a)
ReverseT3 Full agonist Human: 100 μM
(DMR 6 μM)
Hormone produced in the
thyroid gland, liberated
from precursor T4
Deng et al. (2012a)
CXCL17 Chemokine Unknown Not assessed Elevates [Ca2+]i in a
pertussis toxin sensitive
manner
Maravillas-Montero
et al. (2014)
Potency values in bold are those generated using a β-arrestin-2 recruitment assay. Action describes the efﬁcacy of each ligand compared to zaprinast, if known.
modest potency at GPR35 and questions have been raised over
whether they are likely to be produced at concentrations required
for activation of GPR35. Moreover, some of the suggested ligands
are certainly agonists at other GPCRs and/or pharma targets. An
example of the latter, is LPA (mono-acylglycerol-3-phosphate).
Derivatives of LPA, including 2-oleoyl LPA and 2-linoleoyl LPA,
were shown to stimulate [Ca2+]i mobilization above the level of
[Ca2+]i produced by endogenously expressed LPA receptors in
HEK 293 cells stably expressing human GPR35 (Oka et al., 2010).
Since a number of other ligands that activate GPR35 have not
been shown to promote coupling to the Gαq pathway (Jenkins
et al., 2011, 2012; Mackenzie et al., 2011), this study could suggest
a novel route for GPR35 stimulated signaling in which certain lig-
ands are‘biased’ in their function (Shonberg et al., 2014). However,
the capacity of these [Ca2+]i responses to be blocked by a GPR35
antagonist were not assessed, since no such ligands were available
at that time and, therefore, this reported effect has not been intrin-
sically linkedwithGPR35 activity. Since LPA species certainly exert
effects through a number of cellular proteins that form the speciﬁc
sub-family of GPCRs named LPA1−6, it is unlikely that LPA acts
with a potency that is selective toward GPR35 (Oka et al., 2010).
Furthermore, LPA apparently does not stimulate recruitment of β-
arrestin-2 to GPR35 (Southern et al., 2013), indicating that it acts
in amanner distinct from themajority of otherGPR35 ligands and,
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therefore, once again may display ‘bias’. Since LPA is associated
with numerous pathological conditions including atherosclerosis
(Schober and Siess, 2012), cancer (Gotoh et al., 2012), obesity,
impaired glucose homeostasis (Rancoule et al., 2014), and pain
(Ueda et al., 2013), there is a need to clarify the relevance of this
reported effect of LPA at GPR35.
The L-kynurenine metabolite kynurenic acid (4-oxo-1H-
quinoline-2-carboxylic acid) is certainly able to promote acti-
vation of GPR35 (Wang et al., 2006). Although best known as
a neuroprotective modulator through interaction with various
receptors in the central nervous system (Mackenzie et al., 2011),
many of these studies have not considered a role for GPR35,
because early distribution studies suggested that this receptor is
not highly expressed in the brain (O’Dowd et al., 1998; Wang
et al., 2006). However, GPR35 has received attention as a poten-
tial modulator of the effects of kynurenic acid in the periphery
(Moroni et al., 2012; Thorburn et al., 2014), although the level of
kynurenic acid reported to occur in the gut and the concentra-
tion required to activate GPR35 does not appear to overlap, at
least in humans (Jenkins et al., 2011; Milligan, 2011). In phar-
macological assays, addition of kynurenic acid was found to
mobilize [Ca2+]i following transfection of GPR35 alongside a
cocktail of Gαq-based G protein chimeras with a EC50 of 39 μM
at human, 11 μM at mouse, and 7 μM at rat (Wang et al.,
2006). Thus, a degree of species selectivity was observed between
the human and rodent orthologs of GPR35 with kynurenic acid
displaying higher potency at rat than at human (Wang et al.,
2006). This proﬁle was also observed in an independent study
using HEK293 cells transiently expressing C-terminally manip-
ulated forms of GPR35 and β-arrestin-2, which used a BRET
assay, and generated an EC50 of 66 μM for rat GPR35-eYFP
and >100 μM at the equivalent human construct (Jenkins et al.,
2011).
In a concerted effort to deorphanize a panel of 82 orphan
GPCRs, scientists from Medical Research Council Technology
and GlaxoSmithKline screened 10,500 candidate endogenous lig-
ands using the DiscoveRx PathHunter™ β-arrestin-2 recruitment
assay (Southern et al., 2013). In this screen, the second mes-
senger cGMP was identiﬁed as a putative endogenous ligand
of human GPR35. Subsequently, the derivatives MANT cGMP
(2′-O-(N-methylanthraniloyl)-cGMP) and db-cGMP (dibutyryl-
cGMP) were also identiﬁed as activators of human GPR35
(Southern et al., 2013). MANT-cGMP (EC50 2 μM) was the
most potent of these, with cGMP being the least potent (EC50
130 μM; Southern et al., 2013). The functional relevance of these
ligands at GPR35 remains to be demonstrated, including whether
concentrations of cGMP present in vivo would be sufﬁcient to
activate GPR35. Notwithstanding, it is interesting to note that
cGMP and its associated signaling pathways have received con-
siderable attention recently for the treatment of cardiovascular
disorders including hypertrophy, hypertension, ischemia, and
reperfusion injury (Garcia-Dorado et al., 2009; van Heerebeek
et al., 2012; Greene et al., 2013; Lukowski et al., 2014), and the
possible link between GPR35 and cGMP may therefore deserve
further attention.
An assessment of tyrosine pathway metabolic intermediates
that contain catechol or carboxylic acid groups revealed that the
melanin biosynthesis intermediate DHICA (5,6-dihydroxyindole-
2-carboxylic acid) and thyroid hormone synthesis interme-
diates T3 (3,5,3′ triiodothyronine) and reverse T3 (3,3′,5′-
triiodothyronine) promoted DMR in the human colorectal
adenocarcinoma cell line HT-29 (Deng et al., 2012a). Applica-
tion of the synthetic GPR35 antagonist CID-2745687 (methyl-
5-[(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-diﬂ-
uorophenyl)pyrazole-4 carboxylate) at a ﬁxed concentration of
64 μM reduced the wavelength shift of each of the aforemen-
tioned agonists to almost basal levels, indicating that their activity
occurred primarily through GPR35, which is expressed endoge-
nously in these cells. However, conﬁrmation of these responses in
an independent assay utilizing a β-lactamase reporter gene-based
readout of β-arrestin recruitment suggested that only DHICA
acted with similar potency to that generated in the DMR for-
mat (Deng et al., 2012a). This indicated that T3 and reverse
T3, if acting through GPR35, do so in a functionally selective
manner. Reverse T3 was found to be the most potent of the
tyrosine metabolites assessed, generating DMR in HT-29 cells
with an EC50 of 5.9 ± 0.4 μM (Deng et al., 2012a). The EC50
observed in the Tango™ β-arrestin recruitment assay, however,
was substantially higher, at 108 ± 9 μM. T3 was less potent than
reverse T3, with an EC50 of 50 ± 5 μM in the DMR assay and
513 ± 61 μM in the Tango™ assay (Deng et al., 2012a). How-
ever, estimates of the free and total levels of T3 and reverse T3
in the literature (Chopra et al., 1975; Hüfner and Grussendorf,
1978; Prescott et al., 1979) indicate that it is unlikely that the con-
centrations of these molecules produced in man could activate
GPR35 signiﬁcantly in vivo (Deng et al., 2012a). Nonetheless, it
is interesting to note that the levels of reverse T3 were found
to increase, and T3 to decrease, following acute myocardial
infarction (Friberg et al., 2002) and in advanced heart failure
(Hamilton et al., 1990), and have been utilized as a measure
to predict survival rates in patients with heart disease (Iervasi
et al., 2003). Thus, akin to kynurenic acid, it appears that the
levels of these molecules present in the plasma of humans are
below the threshold required to activate GPR35 under normal
physiological conditions, although their actions at GPR35 may
be relevant when plasma levels are altered, for example during
disease.
The most recent suggestion of an endogenous ligand for
GPR35 is perhaps the most intriguing. Maravillas-Montero et al.
(2014) have shown that the chemokine CXCL17 is able to ele-
vate [Ca2+]i in both HEK293 cells transfected to express human
GPR35 and in the human monocytic cell line THP-1. More-
over, effects were produced at modest concentrations of the
chemokine and this ligand was able to promote chemotaxis of
THP-1 cells (Maravillas-Montero et al., 2014). The authors fur-
ther highlighted similarities in sequence between GPR35 and
more traditional chemokine receptors, going so far as to suggest
the renaming of GPR35 as ‘CXCR8’ (Maravillas-Montero et al.,
2014).
SYNTHETIC LIGANDS FOR GPR35
Consensus may not have been reached on whether GPR35 is
truly activated by any of the aforementioned endogenous ligands
in vivo (Mackenzie et al., 2011; Milligan, 2011), yet progress in
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the identiﬁcation of synthetic surrogate ligands for this recep-
tor has been quite successful (Table 2). Focused compound
discovery efforts carried out by both the industrial and aca-
demic sectors have reported a number of compounds that display
moderate-to-high potency at GPR35, and indeed there now exists
a reasonable number of tool compounds with which to probe the
basic physiology and pathophysiology of this receptor. Notably,
however, as observed for kynurenic acid, many of these syn-
thetic compounds display marked species selectivity. For this
reason, care must be taken when selecting the compound of
choice for any form of study in rodents, because the majority
of screens have been conducted initially on human GPR35 and
markedly human-selective molecules will generate negative results
in rodents.
One of the earliest and most useful ligands reported to have
activity at GPR35 is the cGMP phosphodiesterase inhibitor, zapri-
nast (2-(2-propyloxyphenyl)-8-azapurin-6-one) (Taniguchi et al.,
2006). Zaprinast tends to be employed as a reference agonist for
GPR35 since it displays moderate-to-high potency at each of the
human, mouse, and rat species orthologs (Taniguchi et al., 2006;
Yang et al., 2010; Jenkins et al., 2012), and zaprinast’s GPR35-
mediated effects can be dissected from those exerted through
its inhibition of cGMP phosphodiesterases (Yoon et al., 2005;
Taniguchi et al., 2006; Choi et al., 2007). Moreover, the capacity
of a cGMP phosphodiesterase inhibitor to interact with GPR35
was, in part, the rationale for exploring whether cGMP might be
an endogenous agonist of GPR35 (Southern et al., 2013). How-
ever, despite the wide application of zaprinast as reference agonist
of GPR35, with reported potency of between 2 and 8 μM at
the human ortholog, concerted efforts have been taken to iden-
tify agonists with high potency at human GPR35, and ideally
one that acts with similar potency at the human and rodent
orthologs.
A number of ligands that acted with potencies higher than
zaprinast at the human ortholog were subsequently identiﬁed.
These include pamoic acid (5-nitro-2-(3-phenylproplyamino)
benzoic acid), which was identiﬁed independently by two groups
following screens of the Prestwick Chemical Library® (Jenkins
et al., 2010; Zhao et al., 2010). However, the activity of pamoic acid
at the rat and mouse orthologs, at least in the assays most often
employed to screen for ligands at GPR35, is considerably lower
than at human (Table 1), which prevents the use of this ligand
in rodent studies (Jenkins et al., 2010, 2012; Milligan, 2011). This
pattern of species selectivity was also displayed by “compound
1” (4-{(Z)-[(2Z)-2-(2-ﬂuorobenzylidene)-4-oxo-1,3-thiazolidin-
5-ylidene]methyl}benzoic acid) (Neetoo-Isseljee et al., 2013),
and PSB-13253 (6-bromo-8-(4-[(3)H]methoxybenzamido)-4-
oxo-4H-chromene-2-carboxylic acid) (Funke et al., 2013), which
both display potency similar to pamoic acid at human GPR35
and act with signiﬁcantly lower potency and efﬁcacy at the
rodent orthologs (Table 1). Compound 1 was identiﬁed fol-
lowing a screen of the Medical Research Council Technol-
ogy 100,000 small molecule compound collection using the
DiscoveRx enzyme complementation β-arrestin-2 recruitment
assay (Neetoo-Isseljee et al., 2013), as were four other, chem-
ically distinct, GPR35 agonists that display various proﬁles of
species selectivity (Neetoo-Isseljee et al., 2013), while PSB-13253
was derived from a medicinal chemistry program based on
derivatives of chromen-4-one-2-carboxylic acid (Funke et al.,
2013).
The study by Funke et al. (2013) also presented the ﬁrst
comprehensive assessment of the structure-activity relationship
between various chemical structures at human, mouse, and rat
orthologs of GPR35. Although noted previously for individual
ligands (Neetoo-Isseljee et al., 2013), this study provided collec-
tive evidence that GPR35 ligands act with either human-selective,
human-and-mouse-selective, human-and-rat-selective or rodent-
selective properties, with no ligands found to act with high
and equal potency at all three orthologs (Funke et al., 2013).
However, shortly after this study was published, two mast cell
stabilizers were found to activate human and rat GPR35 in
a high and equipotent manner, becoming the ﬁrst tool com-
pounds reported that could feasibly be employed to translate
the ﬁndings obtained for the human receptor in vitro into
in vivo physiological studies in rat models of physiology and
disease (Mackenzie et al., 2014). In the BRET-based β-arrestin-
2 recruitment assay, lodoxamide (2,2′-[(2-chloro-5-cyano-1,3-
phenylene)diimino]bis[2-oxoacetic acid]) and bufrolin (6-butyl-
4,10-dioxo-1,7-dihydro-1,7-phenanthroline-2,8-dicarboxylic acid)
activated GPR35 with respective EC50s of 3.6 nM and 12.5 nM at
human and 12.5 nM and 10 nM at rat (Mackenzie et al., 2014).
This study also identiﬁed a number of mast cell stabilizers that act
with rat-selectivity at GPR35 orthologs, including amlexanox and
pemirolast (Table 3).
RECEPTOR HOMOLOGY MODELING EFFORTS INDICATE THAT
THE BINDING POCKETS OF HUMAN AND RAT GPR35 ARE
DISTINCT
Over the past 16 years, the lack of highly potent and species-
equipotent tool compounds has greatly hindered progress in
the elucidation of GPR35 function. However, assessment of the
pharmacological differences between species has been useful in
characterizing the ligand binding pocket of this GPCR. This
approach was taken by Mackenzie et al. (2014), who used the
differences in species selectivity at GPR35 to identify residues
involved in ligand function. Based on the knowledge that the
majority of GPR35 ligands contain at least one carboxyl group
(Jenkins et al., 2010; Deng et al., 2011b, 2012b; Deng and Fang,
2012; Funke et al., 2013; Thimm et al., 2013), or a bioisostere
of a carboxyl group (Mackenzie et al., 2014), it was postulated
that positively charged residues within the generic ligand bind-
ing pocket of GPR35 that differed between human and rat might
mediate the differences in potency. To this end, “species swap”
mutations were carried out to switch key arginine residues posi-
tioned within proposed ligand binding regions (Venkatakrishnan
et al., 2013) to the equivalent non-arginine residue in the oppo-
site species ortholog. Mutagenesis efforts using these species swap
mutations indicated that arginine residues present in extracellu-
lar loops 2 and 3 (or at the very top of transmembrane domain
helices 6 and 7 (R164, R6.58, R7.32)) were important for ligand-
induced β-arrestin-2 recruitment to human GPR35, while rat
GPR35 was dependent on the species-conserved residue R4.60
at the extracellular end of transmembrane domain 4 (Mackenzie
et al., 2014).
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Table 2 | Potent synthetic ligands with activity at GPR35.
Name Structure Action Potency
(EC50/IC50)
Comments Reference
Zaprinast, M&B
22,948
Full agonist Human: 2–8 μM
Mouse: 1 μM
Rat: 100 nM
Xanthine derivative; cGMP PDE
5, 6, 9 inhibitor, selective for
PDE 5 (IC50 750 nM)
Taniguchi et al. (2006),
Jenkins et al. (2012)
Pamoic acid Partial agonist at
human, weak
activity at rodent
Human: 30–50 nM
Mouse: Inactive
Rat: >100 μM
Added as an “inert” substance
to pharmaceutical agents;
inhibits DNA pol β (IC50 9 μM)
Jenkins et al. (2010,
2012), Neubig (2010),
Zhao et al. (2010)
“Compound 1” Full agonist at
human, partial
agonist at rodent
Human: 26 nM
Mouse: 17 μM
Rat: 8 μM
Novel ligand Neetoo-Isseljee et al.
(2013)
PSB-13253 Full agonist at
human, partial
agonist at rat
Human: 12 nM
Mouse: Inactive
Rat: 1.4 μM
Novel ligand; [3H] radiolabelled
structure also available with KD
of 5.3 nM
Funke et al. (2013),
Thimm et al. (2013)
Lodoxamide, ICI
74917
Full agonist Human: 4 nM
Rat: 13 nM
Mast cell stabilizer; ophthalmic
solution: Alamide® lodoxamide
tromethamine, U-42,585E
Mackenzie et al.
(2014)
Bufrolin,
BRL10833
Full agonist Human: 13 nM
Rat: 10 nM
Mast cell stabilizer; equipotent
at human and rat GPR35
Mackenzie et al.
(2014)
ML145,
CID-2286812
Inverse agonist Human: ∼25 nM Novel ligand; displays marked
selectivity toward human
GPR35
Heynen-Genel et al.
(2010), Jenkins et al.
(2012)
(Continued)
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Table 2 | Continued
Name Structure Action Potency
(EC50/IC50)
Comments Reference
CID-2745687,
SPB05142,
ML194
Inverse agonist Human: ∼200 nM Novel ligand; displays marked
selectivity toward human
GPR35
Zhao et al. (2010),
Heynen-Genel et al.
(2011), Jenkins et al.
(2012)
Potency values in bold are those generated using a β-arrestin-2 recruitment assay. Action describes the efﬁcacy of each ligand compared to zaprinast, if known.
Receptor homology modeling efforts based on the protease-
activated receptor 1 structure (the most closely related GPCR to
GPR35 for which an atomic level structure is known) indicated
that the species-equipotent ligands behaved like human-selective
ligands at the human receptor and rat-selective ligands at the
rat receptor (Mackenzie et al., 2014), i.e., in order to generate
an equipotent response the ligand must bind differently to each
ortholog (Figure 1). A number of similar residues were impli-
cated in GPR35 ligand binding in an independent study, in which
alanine substitutions were generated at putative ligand-binding
residues, and the resultingmutants functionally assessed in a num-
ber of distinct assay formats including β-arrestin-2 translocation,
extracellular-signal regulated kinase phosphorylation and calcium
mobilization (Zhao et al., 2014). In conjunction with receptor
homology modeling efforts based on the β2-adrenoceptor, argi-
nine residues at positions 4.60, 164, 167, and 6.58 were found
to be involved in the binding and/or function of zaprinast and
pamoic acid at human GPR35 (Zhao et al., 2014).
GPR35 COUPLES TO BOTH Gαi/o AND Gα13 SUBUNITS AND
RECRUITS β-ARRESTIN-2
Alongside efforts to understand the mode of ligand binding to
GPR35, downstream signaling and responses following GPR35
activation have been studied in an attempt to characterize path-
ways in which the receptor is involved and, thereby, understand
the physiology and function of the receptor. Several signaling
mediators that directly interact with GPR35 have been iden-
tiﬁed, and provide insight into the pathways and responses
that could potentially be targeted through its pharmacological
manipulation.
In terms of classical GPCR signaling, GPR35 appears to couple
to various Gα subunits depending on the cell type and/or back-
ground species. Kynurenic acid-induced binding of [35S]-GTPγS
induced by human GPR35 heterologously expressed in Chinese
hamster ovary cells was inhibited byBordetella pertussis toxin (Per-
tussis toxin), which is known to speciﬁcally disrupt coupling to
Gαi/o family G proteins (Wang et al., 2006). Furthermore,Ohshiro
et al. (2008) demonstrated that in Chinese hamster ovary cells
transfected with rat GPR35, kynurenic acid and zaprinast both
inhibited forskolin-induced cyclic adenosine 3′ 5′ monophosphate
(cAMP) generation, also indicating an involvement of one ormore
adenylate cyclase-inhibiting Gαi/o family G proteins. GPR35-
dependent effects on N-type calcium channels in rat neurons
heterologously expressing human GPR35 have also been shown
to be sensitive to Pertussis toxin (Guo et al., 2008). It is also inter-
esting in this regard that the recent demonstration of CXCL17 as a
potential GPR35 agonist indicated that both chemotaxis of HTP-1
cells and elevation of [Ca2+]i levels in HEK293 cells transfected
with the human ortholog of GPR35 were also blocked by pretreat-
ment of the cells with Pertussis toxin (Maravillas-Montero et al.,
2014).
As well as such effects, coupling to the Gα13 subunit, which
activates guanine nucleotide exchange factors that promote GTP
exchange to activate Rho family GTPases (Tanabe et al., 2004), has
been observed in a human cell line. Zaprinast-induced activa-
tion of Gα13 was demonstrated using an activation state-sensing
GTP-Gα13 antibody in transfected HEK293 cells (Jenkins et al.,
2011). This was observed for human GPR35 and for rat GPR35.
The same study also demonstrated the ability of zaprinast to
induce [Ca2+]i increases in HEK293 cells co-transfected with a
chimeric Gαq/Gα13 G protein subunit and either human or rat
GPR35, an effect that was speciﬁc for the Gα13 chimera compared
with the related Gα12 subunit. However, no direct coupling to
the Gq/G11 group of G proteins, that are the routine transduc-
ers of phospholipase Cβ1-mediated elevation of [Ca2+]i has been
reported. The ﬁndings of speciﬁc roles for Gα13 are especially
interesting considering that GPR55, the receptor phylogenetically
closest to GPR35, also displays this unusual coupling speciﬁcity
(Ryberg et al., 2007). Thus, the canonical G protein-mediated cel-
lular and biological effects of GPR35 appear to be largely mediated
by either Gαi/o or Gα13 pathways. However, it is also possible that
G protein coupling effectiveness might be dependent on addi-
tional factors that have yet to be explored systematically, such
as ligand bias or Gα subunit expression. The possibility of lig-
and bias is particularly interesting in the context of GPR35 as a
therapeutic target because, once deciphered, this feature could be
exploited to increase the speciﬁcity of drug-induced responses.
At present, current ﬁndings provide a basis for further study of
these G protein-mediated pathways in the search for a function
for GPR35.
As well as initiatingG protein-dependent responses, GPR35 has
been shown to directly recruit β-arrestin-2 upon stimulation with
various agonists, including kynurenic acid and zaprinast (Jenkins
et al., 2010). This is followed by agonist-dependent internalization
of the receptor, which is presumably mediated by β-arrestin-2 as
per the classical model for GPCR desensitization (Goodman et al.,
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Table 3 | Selection of other synthetic GPR35 ligands.
Name Structure Action Potency (EC50) Comments Reference
Amlexanox,
Amoxanox,
AA-673
Partial agonist Human: 4 μM
Rat: 23 nM
Mast cell stabilizer;
anti-asthma and
anti-allergy medication;
used to treat aphthous
ulcers (Aphthasol®);
inhibits TBK1 and IKK-ε
Neetoo-Isseljee et al.
(2013), Reilly et al. (2013),
Southern et al. (2013),
Mackenzie et al. (2014)
Cromolyn,
sodium
cromoglicate,
DSCG
Full agonist Human: ∼7 μM
Mouse: 22–56 μM
Rat: ∼4 μM
Mast cell stabilizer,
prophylactic agent
against asthma attacks
(Intal®); mast cell
stabilizer and ophthalmic
solution (Opticrom®)
Yang et al. (2010), Jenkins
et al. (2010), Deng et al.
(2012a), Mackenzie et al.
(2014)
Doxantrazole Partial agonist
at human, full
agonist at rat
Human: 3.4 μM
Rat: 300 nM
Mast cell stabilizer Mackenzie et al. (2014)
Furosemide Partial agonist Human: 8.3 μM
([Ca2+]i)
Loop diuretic; congestive
heart failure and edema
treatment; anti-asthma,
anti-inﬂammatory agent
Yang et al. (2012),
Neetoo-Isseljee et al.
(2013)
Pemirolast, TBX Full agonist Human: Inactive
Rat: 95 nM
Mast cell stabilizer,
ophthalmic solution
pemirolast potassium
(Alamast®)
Mackenzie et al. (2014)
Tyrphostin-51 Full agonist Human: 8 μM
(DMR 120 nM)
Identiﬁed from a library
of kinase inhibitors;
prevents tyrosine
phosphorylation
Deng et al. (2011a)
YE210 Full agonist Human: 15 μM
(DMR 64 nM)
Identiﬁed from a library
of intermediates
designed for non-linear
optics and organic
ﬁeld-effect transistors
Deng et al. (2011b)
2,3,5-THB Partial agonist Human: 8.4 μM
(DMR 250 nM)
Metabolite of aspirin Deng and Fang (2012)
Potency values in bold are those generated using a β-arrestin-2 recruitment assay. Action describes the efﬁcacy of each ligand compared to zaprinast, if known.
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FIGURE 1 | Receptor homology modeling of human and rat GPR35
indicates residues important for ligand binding. Based on homology
modeling efforts with the protease-activated receptor 1 and mutagenesis
studies, residues important in lodoxamide (A,C) or bufrolin (B,D) function at
human (A,B) or rat GPR35 (C,D) were identiﬁed. The Figure is taken with
permission, from Mackenzie et al. (2014).
1996; Mackenzie et al., 2014). For many GPCRs, β-arrestins have
now also been shown to function as signaling scaffolds, inter-
acting with a number of different pathways including the c-Jun
N-terminal kinase, protein kinase B and cAMPpathways, butmost
notably the extracellular signal-regulated kinase (ERK1/2) path-
way (Luttrell andGesty-Palmer, 2010), in aGprotein-independent
manner. Whether this is the case for GPR35 remains to be deter-
mined, but given the diversity of processes seemingly inﬂuenced
by GPR35, discussed below, screening for biased ligands may be
key to understanding the physiological functions of this receptor
and harnessing it as a therapeutic target.
GPR35 AS A THERAPEUTIC TARGET
Amid uncertainty regarding the endogenous ligand of GPR35 and
the complex nature of its G protein coupling proﬁle, its physi-
ological function and importance remain poorly understood. In
recent years, however, the receptor has been associatedwith a range
of diseases spanning multiple biological systems, which hints at
its far-reaching potential as a therapeutic target. It will therefore
be necessary to elucidate the physiological role of GPR35, both
in health and disease, in order to utilize what we know of its
pharmacology to develop it as a novel drug target.
EXPRESSION PATTERN
GPR35 mRNA transcripts have been detected in a number of
diverse tissues throughout the body in both rodent and human
studies. The publication that ﬁrst identiﬁed GPR35 attempted to
investigate tissue distribution through Northern blot analysis on
various human and rat tissues (O’Dowd et al., 1998). Although
no data were shown, the authors reported that mRNA expres-
sion was detected in rat intestine but that this was not replicated
in human tissue (O’Dowd et al., 1998). Using the more sensitive
approach of qRT-PCR,Wang et al. (2006) detected mRNA in lung,
stomach, small intestine, colon, and spleen in both human and
mouse tissues, and in human peripheral lymphocytes. In situ
hybridization with GPR35 RNA probes in a mouse tissue array
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revealed expression throughout the lower digestive tract, with
hybridization in the duodenum, jejunum, ileum, cecum, colon,
and rectum (Wang et al., 2006). Similarly, qRT-PCR in rat detected
high levels of GPR35 mRNA in lung, stomach, small intestine, and
colon, but also skeletal muscle, dorsal root ganglion and uterus,
with moderate expression in spinal cord, heart, liver, bladder,
whole brain, and cerebrum (Taniguchi et al., 2006). Expression
in the rat spinal cord and dorsal root ganglion has since been
corroborated (Ohshiro et al., 2008; Cosi et al., 2011), as well as
expression in mouse astrocytes (Berlinguer-Palmini et al., 2013).
Finally, GPR35 mRNA has also been found in various human
immune cells, including mast cells, basophils, and eosinophils
(Yang et al., 2010), and invariant natural killer-like T cells (Fallarini
et al., 2010).
GASTROINTESTINAL AND METABOLIC DISEASES
Based on the high expression levels of GPR35 in the gastrointesti-
nal tract, it seems logical that the receptor should have a function
in gut homeostasis. Indeed, GPR35 has been proposed as a risk
factor for chronic inﬂammatory disorders of the gut such as IBD
and ulcerative colitis. The ﬁrst such report comprised a GWAS for
early onset IBD (including Crohn’s disease and ulcerative colitis),
which identiﬁed a GPR35 SNP associated with ulcerative colitis
(Imielinski et al., 2009). The SNP at rs4676410 is an upstream
intron variant of GPR35 encoding a cytosine to thymine substi-
tution, although no change in GPR35 expression was observed
in tissue from individuals with IBD compared with that from
genetically related controls. However, the same SNP was also asso-
ciated with CAPN10, KIF1A, and RNPEPL1 genes in a linkage
disequilibrium block, and CAPN10, which encodes the calcium-
regulated intracellular cysteine protease calpain 10, was found
to be expressed at signiﬁcantly lower levels in individuals with
ulcerative colitis.
Prior to the IBD GWAS, the neighboring genes CAPN10
and GPR35 had both previously been linked with disease in
a GWAS for type 2 diabetes mellitus (Horikawa et al., 2000).
This study identiﬁed four non-synonymous SNPs in the cod-
ing region of GPR35, with only ‘UCSNP-38,’ which encodes
a serine to arginine substitution at amino acid position 294,
showing an association with type 2 diabetes. However, no
evidence of linkage was found for GPR35, whereas ‘UCSNP-
43’ in CAPN10 displayed both association with type 2 dia-
betes and evidence for linkage. The study therefore concluded
that the genetic variation in CAPN10, and not GPR35, was
responsible for the disease susceptibility, and no further evi-
dence for a role of GPR35 in type 2 diabetes has since been
reported.
A more recent study into ulcerative colitis and primary scle-
rosing cholangitis, a chronic cholestatic liver disease, has fur-
ther suggested involvement of GPR35 in IBD (Ellinghaus et al.,
2013). The majority of primary sclerosing cholangitis patients
have concurrent ulcerative colitis, and integrated analysis of
GWAS studies for both diseases identiﬁed two GPR35 SNPs as
having a signiﬁcant association with primary sclerosing cholan-
gitis (Ellinghaus et al., 2013). One of these was the rs4676410
upstream intron variant previously identiﬁed in the IBD GWAS
(Imielinski et al., 2009), whereas the other, at rs3749171, encodes
a methionine to threonine substitution in the third transmem-
brane domain of the receptor. The authors of this study speculated
that, due to its expression pattern and the presence of kynurenic
acid both in bile and in the gastrointestinal tract in disease
(Forrest et al., 2003; Paluszkiewicz et al., 2009), GPR35 may have
a role in the regulation of inﬂammation in the gastrointesti-
nal and biliary tracts, although this is yet to be examined
experimentally.
CARDIOVASCULAR DISEASE
Although a role for GPR35 in cardiovascular disease is not imme-
diately obvious from its expression proﬁle, the receptor has been
implicated, both directly and indirectly, in several aspects of car-
diovascular dysfunction. The ﬁrst study to suggest a cardiovascular
role for GPR35 was a GWAS of hypertensive individuals, which
aimed to identify novel predictors of coronary artery disease (Sun
et al., 2008). This study identiﬁed an association between a non-
synonymous GPR35 SNP and coronary artery calciﬁcation, a risk
factor in atherosclerosis and coronary artery disease. Interestingly,
the identiﬁed rs3749172 SNP was the same one previously associ-
ated with type 2 diabetes (Horikawa et al., 2000). The SNP causes
a serine to arginine substitution at amino acid position 294 in
the receptor C-terminal tail, the primary domain involved in
binding cytoplasmic proteins other than G proteins. The poly-
morphism may therefore inﬂuence β-arrestin-mediated responses
and consequently alter the selectivity of the G protein- versus β-
arrestin-dependent response. In vitro observations, however, do
not support this hypothesis; the serine to arginine substitution
was found not to alter the potency of a range of ligands in a Path-
Hunter human GPR35-β-arrestin-2 interaction assay (Mackenzie
et al., 2014). However, as serine 294 is a potential site of ligand-
regulated phosphorylation, the importance of this SNP is certainly
worthy of further investigation, not least because this varia-
tion is exceptionally common (reported minor allele frequency
0.494).
Further evidence of an involvement of GPR35 in cardiovascular
disease was found in a global gene expression microarray analysis
of twelve individuals diagnosed with chronic heart failure (Min
et al., 2010). GPR35 expression in myocardial tissue from heart
failure patients was signiﬁcantly upregulated compared with that
in healthy controls, and GPR35 was among twelve genes selected
for follow-up analysis based on its orphan status and its novelty as
a potential therapeutic target. Adenovirus-mediated overexpres-
sion of GPR35 in primary rat cardiomyocytes resulted in reduced
viability and cellular hypertrophy (Min et al., 2010). Measuring
the hemodynamic parameters of GPR35 knockout mice using
a Millar catheter revealed a signiﬁcant 37.5 mmHg increase in
blood pressure in the knockout mice compared with wild type
littermates, which strongly implicates GPR35 in blood pressure
regulation (Min et al., 2010).
A more detailed investigation of GPR35 expression in neonatal
mouse cardiomyocytes found both mRNA and cell surface protein
levels to increase in response tohypoxia andhypoxia-inducible fac-
tor 1 activation (Ronkainen et al., 2014). Considering that hypoxia
is a feature of most chronic cardiac pathologies, this provides a
possible rationale for the apparently broad involvement of GPR35
in cardiovascular disease. In the same study, overexpression of
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GPR35 in neonatal mouse cardiomyocytes led to membrane ruf-
ﬂing and formation of retraction ﬁbers, but no change in cell size.
This conﬂicts with the previous ﬁnding by Min et al. (2010) in rat
cardiomyocytes, suggesting possible species variation in the spe-
ciﬁc cellular effects of GPR35. Nonetheless, both results implicate
GPR35 in regulation of actin cytoskeletal rearrangements. This
is very likely to be mediated through the receptor’s coupling to
Gα13 and its effector RhoA, which are well-established regulators
of actin cytoskeletal remodeling (Siehler, 2009; Thumkeo et al.,
2013).
Inmouse surgicalmodels of both acute hypoxia due tomyocar-
dial infarction and chronic pressure overload (a model of cardiac
hypertrophy and heart failure), GPR35 expression is induced
early on in the heart (after 1 day and 2 weeks, respectively;
Ronkainen et al., 2014). In the chronic model this was found
to precede pathological cardiac remodeling and the develop-
ment of heart failure. These ﬁndings strongly suggest a role for
GPR35 in cardiac pathophysiology, although further research
is required to validate it as a therapeutic target in this con-
text. Taken together, the human and mouse studies highlight
potential uses for GPR35 as a predictive marker in the devel-
opment of heart failure and as a target in the treatment of
hypertension.
IMMUNE HEALTH AND INFLAMMATION
GPR35 has been linked to inﬂammation, primarily in studies in
which addition of GPR35 agonists has attenuated inﬂammatory
processes, leading to the suggestion that GPR35 can modulate
inﬂammatory conditions. GPR35 has been linked to immune
health through dietary intake and digestion of tryptophan-
containing foods such as red meat, ﬁsh, eggs, and vegetables,
which are broken down to generate serotonin, melanin, kynurenic
acid and nicotinamide, amongst others (Thorburn et al., 2014).
In the gut, kynurenic acid can be liberated from dietary pro-
tein through the activity of Escherichia coli and transported to
the extracellular milieu and blood where it elicits broadly anti-
inﬂammatory effects (Kuc et al., 2008). Kynurenic acid was found
to attenuate lipopolysaccharide-induced tumor necrosis factor-
α secretion in human peripheral blood mononuclear cells and
puriﬁed peripheral blood monocytes (Wang et al., 2006). In an
independent study, kynurenic acid treatment of monocytes and
neutrophils induced ﬁrm arrest of intracellular adhesion molecule
1-expressingmonolayers of humanumbilical vein endothelial cells
(Barth et al., 2009). This signal was diminished by Pertussis toxin
treatment and reduced by small hairpin-RNA delivery targeting
GPR35, implicating GPR35 as a direct mediator of leukocyte
adhesion (Barth et al., 2009). However, the potency of kynurenic
acid in these studies was markedly higher than in any study
reported to date that has employed transfection of the receptor
into a heterologous cell background. In invariant natural killer-
like T cells, which are involved in the maturation of dendritic
cells and regulation of autoimmunity, kynurenic acid and zapri-
nast were shown to reduce interleukin-4 release into the culture
medium in a dose-responsive and Pertussis toxin-sensitive man-
ner without signiﬁcantly reducing levels of interferon-γ, although
the physiological signiﬁcance of this is unclear (Fallarini et al.,
2010).
In addition to studies based on kynurenic acid-induced effects,
Yang et al. (2010) demonstrated GPR35 upregulation in response
to challenge with IgE antibodies. The same study reported
potency of anti-allergic, anti-asthma drugs cromolyn disodium
and nedocromil sodium at GPR35, and an independent study
also reported potency of several related mast cell stabilizers
(Tables 2 and 3; Mackenzie et al., 2014). These studies suggest
GPR35 may be involved in inﬂammation mediated by the innate
immune response, and could potentially be targeted in the treat-
ment of inﬂammatory conditions or autoimmunity, although
a much more detailed understanding of the receptor’s role is
required.
The recent report proposingGPR35 to be a chemokine receptor
also suggests a role for GPR35 in the immune system (Maravillas-
Montero et al., 2014). In this study, CXCL17 was shown to induce
a [Ca2+]i ﬂux in a mouse pro-B cell line transfected with GPR35.
CXCL17 is a macrophage chemoattractant, and is upregulated
in idiopathic pulmonary ﬁbrosis (Burkhardt et al., 2012). GPR35
expression, along with that of macrophage markers, was found to
be signiﬁcantly reduced in the lungs of CXCL17 knockout mice,
suggesting that GPR35-expressing macrophages require CXCL17
to migrate to the lungs, where they may play a role in inﬂamma-
tion (Maravillas-Montero et al., 2014). However, this is an isolated
report that conﬂicts with someprevious ﬁndings; therefore further
investigation into this potential role for GPR35 is necessary.
THE CENTRAL NERVOUS SYSTEM AND NOCICEPTION
G protein-coupled receptor 35 has also been suggested to have
actions in the central nervous system following reports of its
expression in rat spinal cord and dorsal root ganglion neu-
rons (Ohshiro et al., 2008; Cosi et al., 2011; Moroni et al., 2012).
Expression in dorsal root ganglion coincided with expression
of transient receptor potential vanilloid subtype 1, a noci-
ceptive neuronal marker (Ohshiro et al., 2008). Once again,
kynurenic acid and zaprinast were shown to inhibit forskolin-
induced cAMP production in a Pertussis toxin-sensitive man-
ner in these neurons, implicating the GPR35/Gαi/o axis as
a potential target in the treatment of pain. In a mouse
“writhing test” pain model, pre-treatment with the kynurenic
acid precursor L-kynurenine or zaprinast signiﬁcantly reduced
the number of writhes by 58% and 54%, respectively (Cosi
et al., 2011). GPR35, therefore, may be useful as an anti-
nociceptive target, although whether this will translate into
humans remains to be determined, especially since expres-
sion in human sensory neurons has not been reported to
date.
A further link with the central nervous system is seen in mouse
cortical astrocytes, in which GPR35 mRNA was detected and
kynurenic acid again inhibited forskolin-induced cAMP produc-
tion, an effect that was abolished by either pre-treatment with the
GPR35 antagonist CID-2745687 or GPR35 mRNA silencing by
siRNA (Berlinguer-Palmini et al., 2013). Once more, however, it
must be noted that CID-2745687 has been reported to be highly
selective for the human ortholog of GPR35 (Jenkins et al., 2012)
bringing into question the mode of action of this compound
in a mouse model. In the same study, both kynurenic acid and
zaprinast altered [Ca2+]i waves in these cells and reduced evoked
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excitatory post-synaptic currents in rat hippocampal neurons.
Although kynurenic acid also acts on N-methyl-D-aspartate and
α7 nicotinic receptors, the effects on intracellular calcium signal-
ing and synaptic currents were insensitive to antagonists of these
receptors, but sensitive to CID-2745687. In addition, the cGMP
phosphodiesterase inhibitor sildenaﬁl failed to reduce synaptic
currents. This strongly suggests that the effects of kynurenic acid
and zaprinast reported in this study are due to their agonism
of GPR35 and not other known targets of these ligands. It is,
therefore, possible that GPR35 plays a role in rodent synaptic
transmission, although, once again, these results are yet to be tested
in human cell models. Nevertheless, GPR35 remains a potential
therapeutic target in the treatment of pain or the prevention of
excitotoxic damage.
CONCLUSION AND FUTURE PERSPECTIVES
The last few years have yielded signiﬁcant advances in our
understanding of GPR35 pharmacology and its physiological
importance. Two major hurdles – a lack of pharmacological tools
and signiﬁcant species-selectivity – have been at least partially
overcome, the former through the discovery and characterization
of several novel synthetic ligands, and the latter through muta-
genesis efforts that have provided insight into the cause of the
species-selectivity, as well as the discovery of equipotent agonists.
Future research efforts can now begin to assess the afﬁnity of lig-
ands for the receptor, which will be particularly useful in linking
ligand-binding residues with functional capabilities. This has been
made possible by the generation of the ﬁrst radiolabeled ligand of
GPR35: [3H]PSB-13253, which is an agonist with reported KD of
5.3 nM at human GPR35 (Thimm et al., 2013). However, since
this molecule is markedly human-selective, assessment of ligand
afﬁnity at the rodent receptors remains a challenge.
The increased repertoire of pharmacological tools can now
be used to further probe GPR35 actions in physiological mod-
els. While current understanding makes GPR35 a promising
candidate for therapeutic targeting given its involvement in a
wide range of physiological and pathophysiological processes,
no study has yet identiﬁed a deﬁnitive, targetable role for
GPR35. This partially stems from a lack of tools; it is hoped
that research efforts will now be directed toward the design of
species equipotent antagonists, because the existing antagonists
ML-145 (2-hydroxy-4-[4-(5Z)-5-[(E)-2-methyl-3-phenylprop-2-
enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl ]butanoyl-
amino]benzoic acid) and CID-275687 (Heynen-Genel et al., 2010,
2011; Zhao et al., 2010) act with almost complete human-
selectivity, and are of no practical use in rodent models (Jenkins
et al., 2012). Equipotent antagonists would enable deﬁnitive con-
clusions about the therapeutic value of GPR35 to be drawn by
providing a means to probe off-target effects in rodent disease
models. However, much of the work described here focuses on
only rodent models, and so future research should also aim to
translate these ﬁndings into clinically relevant models in order to
truly assess the therapeutic value of targeting GPR35.
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